This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report?
by Zacks Equity Research
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
by Zacks Equity Research
KRYS beat on both earnings and sales in the third quarter of 2024. Lead drug Vyjuvek's launch in the United States shows strong uptake.
Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Krystal Biotech (KRYS) delivered earnings and revenue surprises of 8.33% and 0.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Krystal Biotech (KRYS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Krystal Biotech (KRYS) stock based on the movements in the options market lately.
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
by Zacks Equity Research
The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.
All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy
by Zacks Equity Research
Krystal Biotech (KRYS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 0% and 9.11%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
by Zacks Equity Research
EXEL stock surges 20.7% on encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for growth.
Pacira's Exparel Receives Permanent New Product-Specific J-Code
by Zacks Equity Research
PCRX reports that the CMS has assigned a permanent product-specific J-code for Exparel, which is set to facilitate better insurance coverage for the drug.
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
by Zacks Equity Research
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.
Zevra Stock Surges Close to 70% in 3 Months: Here's Why
by Zacks Equity Research
The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
by Zacks Equity Research
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
by Zacks Equity Research
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.
Here's Why Investors Should Consider Buying Corcept Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
by Zacks Equity Research
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
by Zacks Equity Research
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
by Zacks Equity Research
Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the United States.
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
by Zacks Equity Research
ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
by Zacks Equity Research
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
by Zacks Equity Research
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.